Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMA101

Cell therapy (Antigen-specific T cells) · Kills target cells, directed at tumor-associated antigens (TAAs) · developed by Immatics US

Phase 1 Most advanced trial (none active)
IMTX Developer
1 Registered trials

What is IMA101?

IMA101 is a preparation of autologous cytotoxic T-lymphocytes that are isolated from the patient, expanded ex vivo, and reintroduced by intravenous infusion. The cells are selected for their ability to recognize certain tumor-associated antigens, and they target and kill tumor cells. It is studied in cancer and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Antigen-specific T cells)
Targets
tumor-associated antigens (TAAs) (antigen)
Mechanism
Kills target cells, directed at tumor-associated antigens (TAAs)
Therapy area
Oncology
Developer
Immatics US, Inc. (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02876510 Phase 1 Cancer Completed IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerSolid Tumor

More from Immatics US

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind IMA101

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.